| Followers | 140 |
| Posts | 5784 |
| Boards Moderated | 0 |
| Alias Born | 06/09/2020 |
Friday, October 11, 2024 4:11:08 AM
Let's see, what have actually happened?
TLD
... JAMA journal
... MIA certification
... paediatric trials with same clinical trial setup
... from 14 to 120 people at Advent
... biosimilarity testing ongoing for at least two years
... build of GMP production unit
... extreme IP portfolio of patents
... a 14 year long p2 trial with poly-iclc and DCVax-L showing 45% efficacy
... a trial with keytruda and dcvax-l having primary completion date december 1st showing 65% efficacy
... UCLAs Robert Prins having researched in parallel immunotherapy resistance since 2007 with dcvax-l as center ingredient
... Linda Liau having held 4-5 webinars about this since 2019
... no one in management selling shares but fighting for those they have setting up family funds
... linda powers having 30 million nwbo shares
... advent getting part of its services paid with nwbo shares
... liau joining SAB board
... nwbo negotiating great terms in Roswell deal instigating two new already paid for trials
... the british parliamentary group APPGBT having recommended MHRA to approve and NICE to reimburse DCVax-L
... and ... as higher mentioned priority in the report than mRNA vaccines...
... AND poly-iclc combo trial SUDDENLY completed August 2024 instead of 2026
... AND keytruda combo trial SUDDENLY moved 9 months earlier to December 2024 study completion date.
Yeah ... beyond the in your face illegal spoofing having going on for at least 8 years and with lots of evidence to prove it, outlooks are REALLY grim.
Nothing that shows progress, visions, possibilities and faith.
Noooo, let's all chime in for guidance to poor retailers and beg for a press release just in the final days of the approval phase of DCvax-L.
Let's beg so much, that we can sustain this OTC stock board as the most active, read and debated of all stock boards on Ihub ... as is rational for a stock like this.
Have yet a nice fud day, boiler room shills.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM

